Source: INPI Brazil | Analysis by MJZanon
The RPI 2829 reveals Brazil’s vibrant pharmaceutical, biotech, and health-tech IP ecosystem. Key trends include a rise in Class 42/44 trademarks, strategic international pharma patents (notably in immunology, oncology, metabolic diseases), and growing software filings in digital health and AI-powered platforms. Sector convergence is evident: traditional pharma, tech startups, insurers, and even fintechs are securing IP in overlapping fields, foreshadowing new competitive dynamics.
Filing volumes were led by supplement and wellness companies, outpacing traditional pharma players. Classes 42, 44, 5, and 10 dominated filings. São Paulo and the Southeast remain the key regions. Noteworthy trends include the entry of luxury and consumer brands into healthcare and aggressive brand defense by hospital networks and health service providers.
Top filings came from Novartis, Roche, and emerging Chinese biotechs. Key CPC classifications (A61K, A61P, C07K) highlight innovation in immune diseases, metabolic disorders, and gene therapies. The absence of local pharma patent filings marks an opportunity gap. Filings signal strategic moves into Brazil’s treatment landscape for future therapies.
RPI 2829 features a surge in clinic management apps, telemedicine tools, and ICU analytics platforms. Key players include NeoGrid, research institutions, and startups. Technologies range from Java and .NET to AI modules. Programs aim to enhance patient access, service integration, and regulatory compliance.
CPC codes in pharma patents (A61K, A61P, C12N) align with software fields (AI, health analytics), indicating a convergence of treatment innovation and digital care delivery. Filings signal strategic integration of drug development, patient experience, and care platforms. Banks, tech firms, and academic institutions are emerging health-tech players.